|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-07-2144.

Submitted July 18, 2002
Accepted December 18, 2002
A naturally-occurring Tyr143His IIb mutation abolishes IIb 3 function for soluble ligands but retains its ability for mediating cell adhesion and clot retraction: comparison with other mutations causing ligand-binding defects
Teruo Kiyoi, Yoshiaki Tomiyama*, Shigenori Honda, Seiji Tadokoro, Morio Arai, Hirokazu Kashiwagi, Satoru Kosugi, Hisashi Kato, Yoshiyuki Kurata, and Yuji Matsuzawa
Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan
Department of Transfusion, Osaka University, Osaka, Japan
Department of Clinical Pathology, Tokyo Modical College, Tokyo, Japan
* Corresponding author; email: yoshi{at}hp-blood.med.osaka-u.ac.jp.
The molecular basis for the interaction between a prototypic non-I domain integrin, IIb 3 and its ligands remains to be determined. In this study, we have characterized a novel missense mutation (Tyr143His) in IIb associated with a variant type of Glanzmann thrombasthenia. Osaka-12 platelets expressed a substantial amount of IIb 3 (36-41% of control) but failed to bind soluble ligands including high-affinity IIb 3-specific peptidomimetic antagonist. Sequence analysis revealed that Osaka-12 is a compound heterozygote for a single 521T -> C substitution leading to a Tyr143 -> His substitution in IIb and for null expression of IIb mRNA from the maternal allelle. Since Tyr143 is located in W3 4-1 loop of the -propeller domain of IIb, we examined the effects of Tyr143His or Tyr143Ala substitution on the expression and function of IIb 3 and compared them with previously described KO (Arg-Thr insertion between 160 and 161 residues of IIb) and Asp163Ala mutation located in the same loop by employing 293 cells. Each of them abolished the binding function of IIb 3 for soluble ligands without disturbing IIb 3 expression. Since immobilized fibrinogen and fibrin are much higher affinity/avidity ligands for IIb 3, we performed cell adhesion and clot retraction assays. In sharp contrast to KO mutation and Asp163Ala IIb 3, Tyr143His IIb 3 expressing cells still possessed some ability for cell adhesion and clot retraction. Thus, the functional defect induced by Tyr143His IIb is likely due to its allosteric effect rather than a defect in ligand binding site itself. These detailed structure-function analyses would provide better understanding of ligand binding sites in integrins.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Gresele, E. Falcinelli, S. Giannini, P. D'Adamo, A. D'Eustacchio, T. Corazzi, A. M. Mezzasoma, F. Di Bari, G. Guglielmini, L. Cecchetti, et al.
Dominant inheritance of a novel integrin {beta}3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families
Haematologica,
May 1, 2009;
94(5):
663 - 669.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kashiwagi, M. Shiraga, H. Kato, T. Kamae, N. Yamamoto, S. Tadokoro, Y. Kurata, Y. Tomiyama, and Y. Kanakura
Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A
Blood,
August 1, 2005;
106(3):
913 - 921.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|